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ABSTRACT
The Protein Structure Initiative Material Repository
(PSI-MR; http://psimr.asu.edu) provides centralized
storage and distribution for the protein expression
plasmids created by PSI researchers. These
plasmids are a resource that allows the research
community to dissect the biological function of
proteins whose structures have been identified by
the PSI. The plasmid annotation, which includes
the full length sequence, vector information
and associated publications, is stored in a freely
available, searchable database called DNASU
(http://dnasu.asu.edu). Each PSI plasmid is also
linked to a variety of additional resources, which
facilitates cross-referencing of a particular plasmid
to protein annotations and experimental data.
Plasmid samples can be requested directly
through the website. We have also developed a
novel strategy to avoid the most common concern
encountered when distributing plasmids namely, the
complexity of material transfer agreement (MTA)
processing and the resulting delays this causes.
The Expedited Process MTA, in which we created
a network of institutions that agree to the terms of
transfer in advance of a material request, eliminates
these delays. Our hope is that by creating a repos-
itory of expression-ready plasmids and expediting
the process for receiving these plasmids, we
will help accelerate the accessibility and pace of
scientific discovery.
INTRODUCTION
With the completion of the sequencing of the genomes of
human and other organisms, attention has focused on the
characterization and function of proteins, the products of
genes. The availability of sequence data and the growing
impact of structural biology on biomedical research have
prompted many groups to undertake projects in the
emerging ﬁeld of structural genomics. The objective of
the Protein Structure Initiative (PSI) is to solve protein
structures and to make these structures widely available
for clinical and basic studies with the expectation that this
will expand the knowledge of the role of proteins in
normal biological processes and in disease. The goals
of the PSI:Biology are to continue solving protein
structures and to apply high-throughput structural
biology to important biological problems, which includes
encouraging partnerships between structural biologists
and investigators from the biological, biochemical and/
or molecular communities (http://www.nigms.nih
.gov/Initiatives/PSI/psi_biology/).
The PSI comprises a consortium of institutions, each
focusing on a unique set of targets or protein type
(e.g. eukaryotic proteins or membrane proteins). Each
PSI Center has created thousands of plasmid clones con-
taining genes or fragments of genes to be used for protein
expression, puriﬁcation, crystallization and structure
determination. The PSI Material Repository (PSI-MR)
was established in 2006 with the mission of storing, main-
taining and distributing plasmid clones produced by PSI
researchers.
Key goals for all material repositories include reducing
the eﬀort required by depositors to distribute their
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materials by users. Although much of these eﬀorts focus
on the mechanical acts of storage, retrieval and prepara-
tion of samples for shipment, the PSI-MR has found that
the greatest frustrations and longest delays in material
transfer come from the time it takes to negotiate and
obtain the necessary institutional signatures for material
transfer agreements (MTAs).
Historically, legal agreements governing the distribu-
tion, use or publication of biological materials were used
only for material transfers involving industry (1). The
emergence of spin-out biotechnology companies and
industry funding of academic labs in the 1970s started to
blur the lines between academia and industry. The passage
of the Bayh–Dole Act in 1980, which encouraged
universities to seek intellectual property (IP) protection
and licenses, introduced rich new revenue sources for
universities placing further importance on monitoring
research materials developed using federal funding (2,3).
However, an unintended consequence was the increased
necessity to couple the transfer of biological materials
with MTAs (4).
Even when there are no IP issues, most academic
institutions use MTAs to accompany all transfers due to
the other functions of MTAs (5,6). Speciﬁcally, MTAs
outline liability, set distribution limitations, deﬁne appro-
priate usage of the material and ensure that proper credit
is attributed to the materials’ source. And, fundamentally,
an MTA provides a written record of the terms of
a transfer.
However, the current methods for approving MTAs,
which involve numerous people and steps, are prone to
delays caused by seeking mutually agreeable language
(7). Even without disagreement in the language or terms
of the MTA, each step requires an institutional represen-
tative to review the paperwork and make a decision, a step
that is at the mercy of that individual’s busy schedule.
In the worst case, negotiation of the MTA ends without
an agreement, necessitating either a waste of resources to
reproduce what could have been readily obtained or aban-
donment of the experimental approach altogether. Several
eﬀorts have sought to streamline the material transfer
process by using standardized language (8) (www
.hhmi.org/about/research/sc330F.xls and http://scien-
cecommons.org/projects/licensing/) or software automa-
tion to expedite the delivery and acceptance of MTAs.
However, neither of these eﬀorts has been widely
adopted, and when used, they are still prone to
negotiations and bureaucratic delays. Furthermore,
nothing has been developed that successfully allows fast
transfers of materials between academic and industry
laboratories (9).
It is in this context that we developed a revolutionary
method that eliminates delays due to MTAs, the
Expedited Process MTA (EP-MTA). This process,
described here, has been incorporated into the ordering
process of all plasmids on DNASU, and has signiﬁcantly
reduced the amount of time it takes for researchers to
obtain PSI plasmids.
DATABASE DESCRIPTION
Database design
The PSI-MR database and distribution website, DNASU
(http://dnasu.asu.edu), is based upon the previously
described Plasmid Information Database (PlasmID) (10).
Brieﬂy, DNASU/PlasmID comprises an Oracle-based
relational database as the data storage layer, a suite of
Java modules hosted by an application server as the
business logic layer and a web-based presentation layer.
DNASU and PlasmID store each plasmid as a clone
that is composed of a vector plus an insert. This
normalized structure avoids storage of duplicate informa-
tion for families of clones that share the same vector or
insert. Additional annotation includes associated insert
sequence, vector maps and sequence (when available),
growth conditions, selectable marker(s), tags, mutations,
publications, plasmid depositors, and instructions for dis-
tribution, which are stored and searchable in DNASU and
PlasmID.
Database content
The PSI-MR sequence validates, annotates, stores and
distributes the plasmids created by PSI researchers since
its inception in 2000, of which 16000 are already available
through DNASU. Moreover, DNASU stores and
distributes a nearly 100000 plasmids with inserts from
439 organisms in 289 vector backbones (summarized in
Table 1). This includes nearly complete genomic
collections of clones from Saccharomyces cerevisiae (11),
Pseudomonas aeruginosa (12), Bacillus anthracis,
Francisella tularensis (13), Vibrio cholorae (14) and
Yersinia pestis, human and mouse genes from the
ORFeome collaboration (15), and various plasmids from
other researchers
DNASU query features
DNASU and its parent database PlasmID were originally
developed with four basic search options:
(i) Gene identiﬁer, which queries the database ﬁrst by
species and then by (a) gene symbol (b) Genbank
Accession number or (c) Gene ID
Table 1. Clones and genes currently represented in DNASU
No. of plasmids
(vectors)
Homo sapiens 34670 (82)
Saccharomyces cerevisiae 17053 (15)
Bacillus anthracis 9883 (2)
Vibrio cholerae 7464 (4)
Francisella tularensis 4752 (3)
Yersinia pestis 3968 (1)
Pseudomonas aeruginosa 2419 (6)
Mus musculus 2341 (32)
Thermotoga maritime 1358 (6)
Other species (429) 13109 (59)
Empty vectors (no insert) 50
Total 97017 (289)
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the Clone ID
(iii) Vector, which queries selected properties of the vector
such as cloning method (e.g. Gateway), expression
system (e.g. mammalian expression) and/or
polypeptide features (e.g. ﬂuorescent tag) and
(iv) Advanced search, a combined query using keywords,
gene symbol/name, vector name, species, author
name and/or publication information.
The outputs yield a search results page listing the
Clone ID, type of plasmid, links to the applicable model
organism database, oﬃcial gene symbol, gene name, gene
description, reference sequence, vector name and the
vector’s selectable markers. Both Clone ID and vector
name link to internal pages that provide detailed informa-
tion including insert and vector sequence and a vector
map. References to external annotations are also linked
to their corresponding reference directly from the search
output. Plasmids can be requested from the search results
page by clicking the ‘Add to cart’ button.
PSI-MR portal
Database content. The PSI collection is a subset of
the plasmid repository in DNASU. At DNASU, the
‘Plasmid of the Month’ features a PSI plasmid or
plasmid collection that may be of particular use to
researchers. For example, the Center for Eukaryotic
Structural Biology (CESG) tobacco etch virus (TEV)
protease expression construct (16) (Clone ID:
TvCD00084286) enables the removal of fusion tags from
recombinant proteins including those produced by many
PSI plasmids and vectors that incorporate TEV protease
sites. Once a month, we also highlight a PSI plasmid that
encodes a protein of unknown function whose structure
has been solved, which we hope facilitates in dissecting
this protein’s biological function. Similar to the
Functional Sleuth on the PSI SGKB (http://kb
.psi-structuralgenomics.org/KB), this page highlights the
protein structure, links to the plasmid in DNASU, and
indicates other plasmids in our collection with similarity
to the unknown protein.
In addition to protein expression plasmids, DNASU
distributes specialized vector backbones developed and
optimized by the PSI Centers for protein expression in
diﬀerent biological systems (e.g. mammalian, yeast,
E. coli. etc.), for various experimental uses (e.g.
overexpression in mammalian cells, protein puriﬁcation
for crystallization or biochemistry, etc), and in speciﬁc
applications (e.g. with a particular tag, selectable
marker, promoter, induction properties, etc.) (24–28)
(Table 2).
DNASU distributes nearly 50 specialized vectors,
including retroviral and lentiviral vectors used for
cloning or expression in mammalian cells, specialized
vectors for yeast and cell free systems, and vectors with
various tags, markers and cloning strategies (17–21).
These vectors provide a functional resource for biologists
interested in applying this technology to their biological
question of interest.
PSI-MR annotations. The PSI plasmid collection has the
unique advantage that all of the plasmids were created
as part of the well-organized and data-managed PSI
program, which tracks a vast amount of experimental
data for each plasmid. Thus, corresponding database
structures have been included in DNASU to capture
these features.
All PSI plasmids have been tested for their ability to
produce soluble protein, including detailed methods for
puriﬁcation. This information has been documented by
the PSI centers, and tracked in DNASU using a controlled
vocabulary (e.g. protein_soluble, protein_not_soluble,
protein_puriﬁed, etc.). This information allows researchers
to quickly identify and sort for plasmids that will have the
expression characteristics most suited for their experiment.
Additional data compiled by PSI centers are assembled
and incorporated into the PSI SGKB, and reciprocally
linked to the PSI-MR plasmids. The PSI SGKB functions
as a central portal where researchers can access all protein
structures from the Protein Data Bank (PDB) (22), which
includes over 4000 structures solved by the PSI eﬀorts, the
PSI modeling portal, technology portal, publications
portal and information from over 100 additional non-
PSI biological resources. Also part of the PSI SGKB,
the Target DataBase (TargetDB, http://targetdb.pdb
.org) and Protein Expression Puriﬁcation and
Crystallization DataBase (PepcDB, http://pepcdb.pdb
.org) store detailed information about target selection
strategy and progress, experimental protocols used, the
experiments performed for a particular target or various
iterations of the target (e.g. truncations or mutations), and
the reasons for stopping work on a particular target
(23,24). Cross-referencing between the plasmids and
these resources helps engage the scientiﬁc community in
this structural genomics eﬀort in addition to providing all
available experimental information to assist researchers
in identifying the functions of these proteins.
PSI-speciﬁc search. The PSI-speciﬁc search options in
DNASU leverage the additional information stored in
the database for PSI plasmids. With the PSI-MR speciﬁc
search, users can search for plasmids from a particular PSI
Center, a speciﬁc target (searching by TargetDB ID)
or with inserts that have been documented to (i) produce
protein, (ii) produce soluble protein, (iii) produce puriﬁed
protein and (iv) lead to a solved protein structure
(searching by PDB ID). The PSI-speciﬁc search output
then presents the information most relevant to the PSI
and to researchers interested in these plasmids, without
having to click through to the clone information page
(Figure 1). This allows both PSI and outside researchers
to reach experimental and structural information about
each clone more quickly.
Blast search. Many genes are assigned multiple names and
often numerous ID numbers, leading to frustration by
users who often know that a collection contains a gene
of interest but are not sure which identiﬁer to use to ﬁnd
it. Therefore, we have added a Basic Local Alignment
Search Tool (BLAST) (25) search feature in order to
search all of the cDNAs in our database to ﬁnd clones
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Vector name Tags Cloning method Cleavage sites Resistance PSI Site
Bacterial expression vectors
pSpeedET modiﬁed His PIPE cloning TEV protease Kanamycin JCSG
p11 6xHis Restriction enzyme TEV protease Ampicillin MCSG
p15Tv-LIC 6xHis LIC TEV protease Ampicillin MCSG
p283 6xHis Restriction enzyme TEV protease Kanamycin MCSG
pDB.GST GST Restriction enzyme TEV protease Kanamycin BSGC
pDB.HBP HBP Restriction enzyme TEV protease Kanamycin BSGC
pDB.His.MBP 6xHis and MBP Restriction enzyme TEV protease Kanamycin BSGC
pDB.His.NusA 6xHis and NusA Restriction enzyme TEV protease Kanamycin BSGC
pDB.His.TRX 6xHis and thioredoxin Restriction enzyme TEV protease Kanamycin BSGC
pDB.TRX Thioredoxin Restriction enzyme TEV protease Kanamycin BSGC
pDB-HisGST 6xHis and GST Restriction enzyme TEV protease Kanamycin BSGC
pH3c-LIC 8xHis LIC 3C protease Kanamycin CSMP
pHM3C-LIC 6xHis and MBP LIC 3C protease Kanamycin CSMP
pHM6g 6xHis and MBP restriction enzyme TEV protease Kanamycin BSGC
pLIC-CH 8xHis LIC TEV protease Kanamycin CSMP
pLIC-EGFP 8xHis and EGFP LIC TEV protease Kanamycin CSMP
pLIC.HM6g 6xHis and MBP LIC-SmaI TEV protease Ampicillin BSGC
pLICB.H 6xHis LIC-SmaI none Ampicillin BSGC
pLICB.HM 6xHis and MBP LIC-SmaI TEV protease Ampicillin BSGC
pLICB.HV 6xHis LIC-SmaI TEV protease Ampicillin BSGC
pNYCOMPS-LIC-
FH10T+(N term)
10xHis and Flag LIC TEV protease Kanamycin NYCOMPS
pVP13
a Stag, 6xHis and MBP Recombinational TEV protease Ampicillin CESG
pVP16
a 8xHis and MBP Recombinational TEV protease Ampicillin CESG
pVP33A
b 8xHis and MBP Restriction enzyme 3CP and TEV cleavage Ampicillin CESG
pVP33K
b 6xHis and MBP Restriction enzyme 3CP and TEV cleavage Kanamycin CESG
pVP56A
b 8xHis and MBP Restriction enzyme 3CP and TEV cleavage Ampicillin CESG
pVP56K
b 8xHis and MBP Restriction enzyme 3CP and TEV cleavage Kanamycin CESG
pMCSG7
c 6xHis LIC TEV protease Ampicillin MCSG
Cell free expression vectors
pEU-GST-FV
d GST Restriction enzyme 3CP cleavage Ampicillin CESG
pEU-His-FV
d 6xHis Restriction enzyme None Ampicillin CESG
Coexpression vectors
pMCSG11 6xHis LIC TEV protease Chloroamphenicol MCSG
pMCSG12 6xHis tag and Sloop LIC TEV protease Chloroamphenicol MCSG
pMCSG13 6xHis and MBP LIC TEV protease Chloroamphenicol MCSG
pMCSG14 6xHis and GST LIC TEV protease Chloroamphenicol MCSG
pMCSG17 Stag LIC TEV protease Ampicillin MCSG
pMCSG20 Stag and GST LIC TEV protease Ampicillin MCSG
pMCSG21 6xHis LIC TEV protease Spectinomycin MCSG
pMCSG22 6xHis and Sloop LIC TEV protease Spectinomycin MCSG
pMCSG23 6xHis and MBP LIC TEV protease Spectinomycin MCSG
pMCSG24 6xHis and GST LIC TEV protease Spectinomycin MCSG
Vectors for increased solubility
pMCSG9
e 6xHis and MBP LIC TEV protease Ampicillin MCSG
pMCSG10 6xHis and GST LIC TEV protease Ampicillin MCSG
pMCSG19
e 6xHis and MBP LIC TEV and TVMV
protease
Ampicillin MCSG
pMCSG19C 6xHis and MBP LIC TEV and TVMV
protease
Ampicillin MCSG
Screening vectors
pMCSG18 6xHis and GFP LIC TEV protease Ampicillin MCSG
Vectors to decrease protein toxicity
pMCSG8 6xHis and Sloop LIC TEV protease Ampicillin MCSG
Cloning vectors
pMCentr1 attL1-TEV-LIC site-attL2 LIC to make entry vector
for recombinational cloning
TEV protease Zeocin MCSG
pMCentr2 attL1-TEV-LIC site-attL2 LIC to make entry vector
for recombinational cloning
TEV protease Kanamycin MCSG
pMCentr3 attL1-TVMV-LIC site-attL2 Destination vector; LIC to
recombinational cloning
TVMV protease Kanamycin MCSG
His, Histidine tag; PIPE, Polymerase Incomplete Primer Extension; MBP, Maltose binding protein tag; LIC, ligation independent cloning; C3P,
human rhinovirus (HRV) 3C protease cleavage site; TEV, Tobacco Etch Virus protease cleavage site; GST, Glutathione D-transferase tag; GFP,
green ﬂuorescent protein tag; Sloop, Loop of GroEX that binds GroEL; TVMV, Tobacco Vein Mottling Virus Protease; attL1 or attL2, Gateway
recombinational cloning sites; Stag, Small T antigen; JCSG, Joint Center for Structural Genomics; MCSG, Midwest Center for Structural Genomics;
BSGC, Berkeley Structural Genomics Center; NYCOMPS, New York Consortium on Membrane Protein Structure; CESG, Center for Eukaryptoc
Structural Genomics; CSMP, Center for Structures of Membrane Proteins.
aRef. (20);
bRef. (17);
cRef. (19);
dRef. (21);
eRef. (18).
D746 Nucleic AcidsResearch, 2010, Vol.38,Database issueFigure 1. Representative results of a PSI-MR speciﬁc search with all clones with structural information from the PDB (‘*’ in the PDB ID ﬁeld) from
the Joint Center for Structural Genomics. Column headers include the Clone ID, the original clone ID provided by the PSI Center (this functions as
a reference for the PSI and for researchers who already know which PSI clone they are searching for), the PDB ID (external link to PDB structural
information), the PepcDB ID (external link to experimental annotation), species speciﬁc ID (external link to EntrezGene or model organism
databases such as the Saccharomyces Genome Database), gene symbol, gene name, reference sequence, mutation/discrepancy (mutations represent
intended mutations compared to the reference sequence such as active site point mutations, and discrepancies represent unintended diﬀerences in the
insert we provide compared to the reference sequence), vector name and selectable marker (for selection in bacteria or other hosts). Clicking on the
Clone ID links to a clone detail page that provides additional information including the insert sequence, growth conditions of the plasmid, and any
special MTA that is required to receive the plasmid. Inserts provide examples of links to additional annotations. Clicking on the TargetDB ID links
to TargetDB and the status of progress with this target. Clicking on the PDB ID links directly to structural annotation at the PDB.
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sequence of interest. Besides assisting when searching for
clones that are similar to hypothetical genes or genes of
unknown function, it also provides access to our entire
collection of plasmids to researchers who otherwise may
only be familiar with a particular clone collection within
our repository.
PLASMID SHARING AND DISTRIBUTION
Quality control
A critical aspect of plasmid distribution is maintaining
the quality of the sample and the data to ensure that the
researcher receives exactly what was requested. The
material repository uses the same strict quality control
measures for incoming PSI plasmids as we have used for
the rest of our collection, which includes automated data
storage and tracking of the sample at all stages of process-
ing, automated sample handling, and full-length sequence
veriﬁcation. In addition, each plasmid and vector entering
the repository is annotated by a PhD level scientist to
ensure that complete and accurate annotations are pre-
sented to the researcher.
Ordering plasmids. Researchers request plasmids directly
through our ordering website DNASU (http://dnasu.asu
.edu). Once ordered, the plasmids are automatically
picked using a robotic picking station that selects the
correct samples from 96-well plates of glycerol stock
samples stored in 2D barcoded tubes. Plasmids are
grown overnight in media and shipped via FedEx the
next day as glycerol stocks. Since beginning distribution
of PSI plasmids in April 2008, we have ﬁlled 138 orders for
228 PSI plasmids, which accounts for over 12% of all
orders that have been ﬁlled at the repository in the past
year. We have implemented a recharge system, managed
by DNASU, to oﬀset the handling fees associated with
preparing and sending plasmids. In addition, we make
an eﬀort to signiﬁcantly reduce the per-clone costs for
large predetermined collections in order to encourage
high-throughput studies.
Expedited MTA
Concept. In order to simplify and streamline the transfer
of plasmid materials to researchers from the PSI-MR,
we developed an EP-MTA. Based on advice from
the Harvard Medical School Oﬃce of Technology
Development and the Harvard University Oﬃce of
General Counsel, we deﬁned the two central charac-
teristics of this process to be: (i) a large set of material,
which is bundled together as a collection (either physically
or virtually) that can be managed under the same funda-
mental transfer terms and (ii) institutions agree to these
terms ‘in advance’ of any subsequent material requests.
In practice, researchers from ‘in-network’ member
institutions (i.e. institutions that have signed the
Expedited Process Agreement and the Standard Plasmid
Transfer Agreement; see Supplementary Data) request
and receive plasmids from the collection without addi-
tional MTA review by the Oﬃce of Technology Transfer
(OTT). Because in-network institutions have already
legally agreed to the terms of the MTA, their researchers
must only indicate personal agreement to the terms using
an online click-through mechanism at the time of placing
the order. Database tracking makes it straightforward to
regularly notify each OTT of the materials received by its
institution for their records.
This expedited process has been implemented for the
past three years for over 900 orders within a growing
network of 70 public and private, national and interna-
tional institutions whose researchers request materials
from the DNASU/PlasmID and the PSI-MR.
Applying the expedited process to other collections. This
expedited process can be applied broadly to most
material collections at either academic or commercial
institutions, adjusting the transfer terms as appropriate
for the sample type and speciﬁcs of the collection. For
example, this approach could be used for materials that
carry features with IP owned by third parties, such as
plasmid backbones with patented promoters or tags. If
the embedded IP requires a user license, it can be noted
with an addendum to the standard MTA that applies to
speciﬁcally indicated material. Because the entire process
is managed automatically with a database, the IP holder
can be notiﬁed that material including their IP has been
distributed, so that they can contact the recipient about
obtaining a license. This ﬂexible method simpliﬁes and
streamlines biological material transfers, which not only
unburdens technology transfer oﬃcers, but also increases
the accessibility of materials to researchers.
FUTURE OUTLOOK
The creation of a material repository for the PSI plasmid
collection beneﬁts both PSI researchers and the general
biological community. Besides functioning as a backup
archive for data and samples for the PSI centers, the
PSI-MR also provides a centralized location where any
researcher can search for and request plasmids created
at dozens of PSI Centers spread across the USA. The
majority of researchers who access our plasmid collection
are not structural biologists; however, through DNASU,
they are exposed to protein expression plasmids and struc-
tural information from the PSI, making the PSI-MR a
useful portal for nonstructural biologists to become
familiar with structural genomics eﬀorts.
As the PSI moves forward into the next 5-year phase
(PSI:Biology; http://www.nigms.nih.gov/Initiatives/PSI/
psi_biology/), the focus of these structural genomics
eﬀorts is shifting towards a deeper collaboration with
biologists in order to understand the function of
the proteins whose structures are solved by the PSI.
While we will continue veriﬁcation, annotation and distri-
bution of PSI plasmids and vectors, we will also expand
the network of institutions in our EP-MTA program so
that these researchers can receive these plasmids without
delay. We anticipate that this will only increase the neces-
sity and utility of the PSI-MR as a facilitator for the
interactions and the transfer of plasmids between PSI
D748 Nucleic AcidsResearch, 2010, Vol.38,Database issuestructural biologists and the general biological
community.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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